INTRODUCTION
Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) characterized by severe mucosal inflammation and ulceration in the large intestine. This debilitating disease is thought to develop due to exaggerated bacterial stimulation of the mucosal immune system. 1 This may reflect changes in the gut microbiota, as the microbial populations of UC patients are known to be dysbiotic, often showing less biodiversity, fewer beneficial microbes, and increased pathobiont numbers than the microbiota of healthy individuals. 2, 3 Moreover, UC patients often display structural or functional defects in their normally protective colonic mucosal barriers. This includes the intestinal mucus barrier, which is largely dependent on the release of goblet cell-derived mucin (Muc2), the major secretory mucin within the gastrointestinal tract. 4 A highly glycosylated protein, upon its release, Muc2 is hydrated, forming the mucus layer that prevents microbes as well as luminal antigens from contacting the epithelial surface. 5, 6 Several studies on inflamed UC patient tissues have shown reduced goblet cell numbers, and a thinner than normal mucus layer. 7 These changes are not necessarily secondary to disease, but may instead represent a primary defect since functional impairments in mucus are observed in some IBD patients even with inactive disease and in mouse models of IBD prior to overt inflammation. [8] [9] [10] Correspondingly, mice that lack Muc2, or suffer missense mutations in Muc2 that impair its release and function develop spontaneous colitis that depends on the presence of gut microbes. 11, 12 Although clearly demonstrating that impaired function and loss of goblet cells predisposes to colitis, it remains uncertain whether additional or concurrent changes in goblet cell function also have a role. Goblet cells produce important mucosal defense factors like trefoil factor 3 (TFF3) and resistinlike molecule-beta (RELM-b). RELM-b was initially thought to have a role in insulin resistance in rodents; however, it was subsequently found to impact immune regulation and host defense against intestinal nematode infections. 13, 14 RELM-b is secreted apically into the intestinal lumen 15 and regulates susceptibility to intestinal inflammation by promoting mucosal barrier integrity. 16 RELM-b expression is induced by commensal colonization in germ-free mice 17 and its secretion is known to be upregulated in several animal models of gut inflammation. [18] [19] [20] These include dextran sodium sulfate colitis where RELM-b was found to leak into the colonic lamina propria, activating macrophages to secrete the cytokine tumor necrosis factor-a. 21 Interestingly, although RELM-b has been shown to regulate the expression of the antimicrobial lectins RegIIIb and RegIIIg, it is unclear whether it has any role in shaping the gut microbiota.
Based on preliminary studies showing that RELM-b was strongly upregulated in the colons of colitic Muc2-deficient ( À / À ) mice, we tested its role during the spontaneous colitis that develops in these mice. We hypothesized that in the absence of the mucus barrier, goblet cells would release RELMb to protect the colonic mucosal surface by upregulating RegIIIb and RegIIIg to create an antimicrobial zone overlying the epithelium. To test this, we generated mice lacking both Muc2 and RELM-b and compared their colitis development with that in Muc2 À / À mice. Although our hypothesis was partially confirmed, as RegIIIb expression was dramatically induced in Muc2 À / À mice but largely lacking in Muc2 À / À / Retnlb À / À mice, its antimicrobial activity led to a dysbiotic gut microbiome deficient in Lactobacillus spp. Over time, this led to a dramatically worsened clinical course in the Muc2 À / À mice that was reversible by targeted replacement by murine, but not human-derived Lactobacillus spp. These studies demonstrate that it is the goblet cells themselves that drive the colitis in Muc2 À / À mice, by inducing a RELM-b-dependent intestinal microbial dysbiosis.
RESULTS

Muc2
À / À mice rapidly develop spontaneous colitis
Assessment of Muc2
À / À mice raised in our facility confirmed previous reports of spontaneous colitis development under physiological conditions. While Muc2 À / À mice appeared completely healthy just after weaning (1 month), as they aged, they developed progressive diarrhea along with sporadic rectal prolapse (RP) (Figure 1a and b) . Once killed, their colons were found to be thickened and reddish in color, containing soft rather than formed stool. Histological analysis revealed that compared with age-matched C57BL/6 mice, 2-month-old Muc2 À / À mouse colon tissues showed overt crypt hyperplasia, occasional crypt abscesses, as well as modest inflammatory cell infiltration and submucosal edema (Figure 1c) . Staining with Periodic acid-Schiff revealed markedly reduced acidic and neutral staining of mucins in the colons of Muc2 À / À mice (Figure 1d) , however, some staining was still evident; indicating the presence of other mucins.
To assess whether the remaining Periodic acid-Schiff staining reflected compensatory increases in other mucins, transcript levels for Muc3, Muc5AC, Muc6, and Muc13 were assayed. The transcription of these mucin genes in Muc2 À / À mice was similar to levels in C57BL/6 mice, suggesting no overt compensatory response ( Figure 1e) . As goblet cells not only secrete mucins, but also RELM-b and TFF3, we next analyzed their gene transcription. As shown in Figure 1f , a significant 290-fold increase in Retnlb gene transcription was observed in Muc2 À / À mice as compared with C57BL/6 mice. A dramatic increase in RELM-b-positive immunostaining was also observed in Muc2 À / À mice, localizing solely to goblet cells (Figure 1g ). In contrast, little if any RELM-b staining was seen in age-matched C57BL/6 mice. The dramatic elevation in Retnlb was selective, as no significant changes in Tff3 transcript levels, or the TFF3 protein were identified in Muc2 À / À mice, as compared with C57BL/6 mice. Thus, in the absence of Muc2, the goblet cell mediator RELM-b is strongly upregulated.
Spontaneous colitis symptoms are reduced in
To determine whether RELM-b had any role in the spontaneous colitis of Muc2 À / À mice, we generated a mouse strain (Muc2 À / À /Retnlb À / À ) lacking both Muc2 and RELM-b. The F1 and F2 progeny obtained from crossbreeding Retnlb
Muc2
À / À mice were genotyped (Supplementary Figure S1A online) using published primers. 12, 22 Colon tissues from the parental as well as Muc2 À / À /Retnlb À / À mouse strains were immunostained for Muc2 and RELM-b. As expected, Muc2 was readily detected in the goblet cells of C57BL/6 and Retnlb À / À mice, but was undetectable in Muc2 Figures S1B  and S1C) . Similarly, when colon tissues were stained for RELM-b, only Muc2 À / À mice displayed positive staining, whereas it was not detected in healthy C57BL/6 mice, or in mouse strains lacking Retnlb (Supplementary Figures S1D  and S1E ).
Once generated, the Muc2 À / À /Retnlb À / À mice were monitored for breeding success, changes in body weight and clinical symptoms such as RP and stool consistency. Similar to C57BL/6 mice, Muc2
À / À /Retnlb À / À mice were very fertile, producing 4-5 litters of normal size (8-10 pups) over their reproductive lives. In comparison, Muc2 À / À mice only produced 3-4 litters of smaller size (4-8 pups). Moreover, significant differences in body weights were noted between mouse strains as early as 2 months of age. Compared with C57BL/6 mice, Muc2 À / À mice were smaller and weighed significantly less (11, 4 , and 14%) at 2, 4, and 6 months of age, respectively ( Figure 2a) . In contrast, Muc2
mice weighed significantly more (8, 6 , and 5%) than C57BL/6 mice at these time points ( Figure 2a) .
As Muc2 À / À mice aged, they displayed overt symptoms of spontaneous colitis. Prior to reaching 2 months of age, 6% developed overt RP (requiring euthanization), while 17% of the original cohort developed RP between 2 and 4 months of age. Another 17% developed RP between 4 and 6 months of age, reaching a total 40% of Muc2 À / À mice developing RP by 6 months of age. In contrast, only 17% of Muc2
mice developed RP over the same time course, with 3%
developing it before 2 months, 5% between 2 and 4 months and 9% between 4 and 6 months of age ( Figure 2b) . Furthermore, when the two mouse strains were analyzed for stool consistency over their first 6 months, 59% of Muc2 À / À mice developed loose stools, vs. only 30% of Muc2 À / À mice whereas the staining for TFF3 was similar to that in C57BL/6 mice (original magnification Â 630). nX5 per each group, Student's t-test, ***Po0.0001, A, crypt abscess; H&E, hematoxylin and eosin; I, inflammatory cell infiltration; Lu, intestinal lumen; M, mucosa; Muc, mucin; O, edema; PAS, Periodic acid-Schiff; RELM-b, resistin-like molecule-beta; SM, sub-mucosa. Since almost half the Muc2 À / À mice required killing before 6 months of age, we decided to focus future studies on mice at 2 and 4 months of age. Microscopic analysis of hematoxylin and eosin stained colon sections at 2 months revealed modest submucosal edema, crypt hyperplasia as well as mucosal inflammation in both mouse strains. Immune/inflammatory cell infiltration was widespread in the Muc2 À / À mice but less overt in the Muc2 À / À /Retnlb À / À mice, whereas crypt hyperplasia was greater in the Muc2 À / À /Retnlb À / À mice, with total pathology scores roughly similar between the two groups (3.8 ± 0.6 vs. 4.8 ± 0.8; Figure 3a) . Between 2 and 4 months of age, colonic pathology in the Muc2 À / À /Retnlb À / À mice increased only modestly to 7.2±0.5, largely due to the increased immune/inflammatory cell infiltration. In contrast, colonic tissue damage was dramatically greater in 4-month-old
À / À mice. Although edema, crypt hyperplasia, and inflammatory cell infiltration were all increased, their most significant pathological features reflected increased crypt epithelial damage as well as crypt abscesses. As compared with Muc2 À / À /Retnlb À / À mice, Muc2 À / À crypts were highly irregular and distorted in shape, while intercryptal spaces were greatly dilated. Crypt abscesses containing neutrophils and necrotic epithelial cells were rare in Muc2
mice, but very frequent in Muc2 À / À mice (Figure 3b) , along with large numbers of neutrophils found within the crypt epithelium. When quantified, colonic pathology increased a dramatic 250% (12.2 ± 1.6) in Muc2 À / À mice by 4 months of age, reaching a level significantly (Po0.001) greater than that of Muc2 À / À /Retnlb À / À mice ( Figure 3c ).
The differential progression of the colitis observed in Muc2
À / À /Retnlb À / À mice led us to investigate whether it reflected differences in inflammatory and immune cell À / À mice when compared with Muc2 À / À /Retnlb À / À mice. nX15 mice were used for each clinical symptom measured. Twoway ANOVA analysis followed by Bonferroni's post-test was used to calculate time-dependent significance between each group of mice, ***Po0.0001. ANOVA, analysis of variance; Muc, mucin; RELM-b, resistin-like molecule-beta.
recruitment to the colon. Immunostaining for T lymphocytes (CD3 þ ), macrophages (F4/80 þ ), and neutrophils (Ly6g þ ) revealed that all three cell types were in greater abundance in the colons of Muc2 À / À and Muc2 À / À /Retnlb À / À mice, as compared with C57BL/6 tissues (Figure 4a-c). At 2 months of age, T lymphocyte numbers were modestly, but significantly higher in Muc2 À / À mice as compared with Muc2 À / À / Retnlb À / À mice, whereas neutrophil and macrophage numbers were similar. Interestingly, by 4 months of age, macrophage numbers remained constant, whereas T lymphocyte and neutrophil numbers increased in the tissues of Muc2 À / À / Retnlb À / À mice to levels similar to Muc2 À / À mice, despite their comparatively reduced tissue pathology.
We next examined whether any overt differences in inflammatory cytokine gene transcription (tumor necrosis factor-a, interferon-g, interleukin (IL)-6, IL-17F, IL-23) could explain the worsened outcomes in the Muc2 À / À mice. Surprisingly, we noted only minimal differences in transcript levels of these genes between Muc2 À / À mice and Muc2 À / À / Retnlb À / À mice at both 2 and 4 months (Figure 4d and e). The only notable differences were significantly greater IL-22 gene transcription in 2-month-old Muc2 and Muc2 À / À /Retnlb À / À mice. Both mouse strains show a significant increase in colonic histopathology between 2 and 4 months of age, however, the histological damage was more severe in Muc2 À / À mice in comparison with Muc2 À / À /Retnlb À / À mice. (c) Bar graphs represents histological scoring of colon tissues in C57BL/6, Retnlb À / À , Muc2 À / À and Muc2 À / À /Retnlb À / À mice aged 2 and 4 months. A double blinded scoring system was used based on following criteria: (i) hyperplasia (0, no change; 1, 1-50%; 2, 51-100%; 3, 4100%), scored as percentages above the height of C57BL/6 mice; (ii) crypt abscess (0, no abscess; 1, few crypts exhibit abscess; 2, about half of the crypts exhibit abscess; 3, over 70% of the crypts exhibit abscesses); (iii) epithelial integrity (0, no pathological changes detectable; 1, few cells slough; 2, epithelial surface rippled; 3, severely disrupted/damaged, large amount of epithelial cell sloughing); (iv) edema (0, no change; 1, mild change; 2, moderate change, and 3, profound change) and (v) mononuclear and polymorphonuclear cells (0, no change; 1, o20; 2, 21-50; 3, 51-70; 4, 470). 
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À / À mice, whereas both IL-17A and IL-22 gene transcription were comparatively upregulated in 4-month-old Muc2 À / À mice ( Figure 4d and e). Thus, while modest differences were noted in the immune/inflammatory response between the two mouse strains, the exaggerated epithelial pathology seen in the Muc2 À / À mice appears to likely depend on other factors. À / À / Retnlb À / À mice at 4 months of age, these genes were still transcribed at 36-and sixfold higher levels in age-matched Muc2 À / À mice ( Figure 5b) . Based on the dramatic elevation of the RegIIIb gene and the tools available to study this lectin, 23 we focused our subsequent analysis on its expression and function.
Corresponding with RegIIIb's dramatically upregulated transcription, intense and widespread RegIIIb immunostaining localized to the colonic epithelium was found in 2-month-old Muc2 À / À mice, but not in Muc2 À / À /Retnlb À / À mice. By 4 months, modest RegIIIb staining was also observed in the Muc2 À / À /Retnlb À / À mice. Although RegIIIb staining in 4-month Muc2 À / À mice was reduced compared with levels at 2 months, it was still dramatically stronger than that seen in Muc2 À / À /Retnlb À / À mice ( Figure 5c ). Additional western blotting of colonic crypts and whole tissue lysates demonstrated thick RegIIIb bands from Muc2 À / À mouse tissues at both 2 and 4 months of age, whereas the RegIIIb signal was minimal from Figure  S2A) . To determine whether RegIIIb was secreted into the colonic lumen, stool samples from Muc2 À / À mice were probed for RegIIIb by western blotting. RegIIIb was readily detected in the stool of Muc2 À / À mice (Figure 5d ), but not Muc2 À / À / Retnlb À / À mice. Additional western blotting on these same Muc2 À / À stool lysates confirmed distinct bands of RELM-b, whereas it was absent from Retnlb À / À and Muc2 Figure S2B) . To clarify the cellular source of the RegIIIb, co-staining of colon sections revealed substantial RegIIIb staining in cells that were also positive for the epithelial cell marker E-cadherin, confirming epithelial cells as the major source of RegIIIb (Figure 5e ). To determine whether RELM-b could directly induce RegIIIb and RegIIIg lectins, mouse epithelial CMT-93 cells were treated with recombinant RELM-b. At 4 h post treatment, a significant 2.7-and sixfold increase in RegIIIb and RegIIIg transcription (respectively) was observed in RELMb-treated cells as compared with untreated cells (Figure 5f ).
Overall, these results demonstrate that RELM-b exerts significant control over epithelial expression of the antimicrobial lectin RegIIIb in the colons of Muc2 À / À mice.
Commensal microbial dysbiosis in Muc2 À / À mice is exaggerated in the presence of RELM-b
Notably, Muc2
À / À mice were recently shown to carry an aberrant gut microbiome that potentially promotes their colitis. 24 Considering their significant secretion of the antimicrobial lectin RegIIIb, we assessed whether it impacted their microbiota. We first analyzed colon tissues for bacterial localization using a eubacterial (EUB) fluorescent in situ hybridization (FISH) probe that detects all bacteria. Significant numbers of adherent bacteria were noted on the colonic mucosal surface of both Muc2
mice, along with staining in the colonic submucosa suggesting bacterial translocation (Figure 6a ). Quantitation of total commensal microbes in the stool by 4',6'-diamidino-2-phenylindole staining revealed no significant differences between the two mouse strains (Figure 6b ). Using primers specific for 16S ribsosomal RNA, we confirmed that Muc2
mice possess an aberrant microbiota as compared to C57BL/6 mice, including reduced levels of Lactobacilli (Supplementary Figure S3A) . However, when we compared the colon contents of Muc2 À / À and Muc2 À / À /Retnlb À / À mice at the phyla level, Bacteriodetes, and Firmicutes levels were similar, although there was a trend towards more g-Proteobacteria in the Muc2 À / À mice. In contrast, when the colon contents were analyzed at the species level (Segmented Filamentous Bacteria, Lactobacillus spp. and Clostridia spp.), the Muc2 À / À /Retnlb À / À mice were found to carry significantly more Gram þ ve Lactobacilli bacteria (8.5 and 3 fold) than the Muc2 À / À mice at 2 and 4 months respectively (Figure 6c and d) . The retention of Lactobacilli in the colons of Muc2 À / À /Retnlb À / À mice was confirmed by FISH staining, using probes designed to detect several Lactobacilli spp. (Supplementary Figure S3B) .
Considering the dysbiotic microbiota seen in the Muc2
À / À mice, we asked whether it was exposure to these microbes that drove the upregulated RELM-b expression. To test this, 12-week old Muc2 À / À mice were given peroral treatment of 200 ml of an antibiotic mixture for 8 days. A significant reduction in RELM-b immunoreactive goblet cells was noted in colonic sections of antibiotic treated mice in comparison to untreated mice confirming a key role for the microbiota in driving RELMb expression (Supplementary Figure S3C) .
RELM-b induced
RegIIIb mediates the antimicrobial effect on Lactobacilli spp.
While our data indicated that Muc2
À / À mice carried significantly fewer Lactobacilli than Muc2 À / À /Retnlb À / À mice, the basis for this microbial dysbiosis was unclear. Using two Lactobacilli isolates from wildtype mice showing close resemblance to L. gasseri and L. johnsonii sub-species respectively, we tested whether RELM-b exerted any direct antimicrobial activity but found no effect (not shown). We next examined the lectin RegIIIb, testing the effects of recombinant RegIIIb as well as crypt supernatants obtained from 2 and 4 month old Muc2 À / À and Muc2
Western blotting confirmed high levels of the RegIIIb lectin only in the supernatants of the Muc2 À / À mice (Figure 7a) . Upon incubating the mouse Lactobacilli isolates with the crypt 
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À / À /Retnlb À / À supernatants at 2 months promoted bacterial growth, while at 4 months, they showed only minimal antimicrobial activity against Lactobacilli (Figure 7b and c) . In contrast, significant bactericidal effect was observed with supernatants obtained from Muc2 À / À mice (at both 2 and 4 months), as well as with the recombinant RegIIIb, confirming it is likely responsible for the ability of Muc2 À / À mouse lysates to kill Lactobacilli. À / À mice were given drinking water containing either our murine Lactobacilli isolates (1 and 2) or a commercial À / À /Retnlb À / À mice showed significant changes in the makeup of the microbiota at the species level in (c) 2-month and (d) 4-month-old mice. Results were shown as an average of three independent experiments with n ¼ 3-4 per group. T-tests were used to calculate the significance between each taxonomic group from stool samples of Muc2 À / À and Muc2 À / À /Retnlb À / À mice ***Po0.0001. DAPI, 4',6'-diamidino-2-phenylindole; FISH, fluorescent in situ hybridization; Muc, mucin.
source of human probiotics (VSL#3) that contains a mixture of three Lactobacilli spp. The mice were then assessed for colitis at 4 months of age. Hematoxylin and eosin staining and colon pathology scoring of VSL#3 treated mice noted a similarly severe colitis in the untreated and VSL#3 treated mice (Figure 8a ). In addition, VSL#3 treated mice showed frequent RP and watery stools similar to untreated mice (Figure 8b and c) . In contrast, upon analyzing the Muc2 À / À mice treated with the murine Lactobacilli isolates, we noted a significant reduction in crypt abscesses and hyperplasia, submucosal edema, and mononuclear cell infiltration as well as improved maintenance of epithelial integrity, as compared to untreated Muc2 À / À mice (Figure 8d ). In addition, the Lactobacilli treated mice did not develop RP and none manifested diarrheic symptoms, whereas 15.3% of untreated mice exhibited RP and 55% demonstrated loose stools (Figure 8e and f) . To confirm that administration of the Lactobacilli isolates altered the microbiome, 16s ribsosomal RNA analysis of colon contents demonstrated a significant 3.5-fold increase in Lactobacilli levels in mice treated with Lactobacilli but not with VSL3 treatment (Figure 8g) . Furthermore, FISH hybridization on stool samples also showed a fourfold increase in Lactobacilli numbers in the Lactobacilli-treated Muc2 À / À mice as compared with untreated mice (Supplementary Figure S4A) . A dramatic reduction in RELM-b and RegIIIb immunostaining was observed in Lactobacilli-treated mice but not in VSL3 or untreated mice suggesting that the Lactobacilli suppressed antimicrobial responses in the Muc2 À / À mice (Supplementary Figure  S4B) . Interestingly, when IL-17A and IL-22 gene transcript levels were analyzed from colon tissues, a modest increase in IL-17A and a significant increase in IL-22 was observed in Lactobacilli-treated mice (Figure 8h) . Taken together, these results indicate that targeted replacement of murine-derived Lactobacilli can ameliorate colitis in Muc2 À / À mice.
Upregulation of short-chain fatty acids in the colons of
To understand how Lactobacilli treatment suppressed colitis in Muc2 À / À mice, we assayed the production of short-chain fatty acids (SCFA) in the colon contents of these mice. Specific bacterial species such as Lactobacilli are primary degraders of insoluble polysaccharides in the gut. This carbohydrate fermentation under anaerobic conditions produces SCFAs such as acetate, propionate, and butyrate, which protect against colitis and promote gut homeostasis. 25 Our results demonstrated increased production of propionate and acetate in Lactobacillitreated mice when compared with untreated Muc2 À / À mice ( Figure 9a) . These results suggest that one mechanisms by which Lactobacilli spp. treatment attenuates colitis in Muc2 À / À mice is by increasing the production of SCFA.
DISCUSSION
Intestinal goblet cells secrete several mediators including TFF3 and RELM-b, but they are best known for secreting the Muc2 that forms the protective intestinal mucus layer. 26 In fact, several recent studies have highlighted the beneficial role this barrier has by limiting direct bacterial contact with the intestinal mucosa. Notably, mice impaired in the release of Muc2 are predisposed to developing colitis. The original goal of this study was to determine how intestinal goblet cells respond in the absence of Muc2, and whether they compensate by releasing other mediators in the context of colitis. Confirming previous studies, we found that after weaning, Muc2 À / À mice develop colitis, in concert with a dramatic increase in the secretion of another goblet cell mediator, RELM-b. By generating mice lacking both Muc2 and RELM-b, we determined that compared with Muc2 À / À mice, Muc2 À / À / Retnlb À / À mice are delayed in their colitis development. Among its roles, RELM-b upregulated RegIIIb, an antimicrobial lectin that efficiently kills Gram-positive bacteria, causing a microbial dysbiosis that worsens the colitis in Muc2 À / À mice. Furthermore, we showed that targeted treatment with mouse commensal Lactobacilli in Muc2 À / À mice can dramatically reduce their colitis symptoms and pathology. In contrast, treatment with human probiotics was unable to resolve the colitis, highlighting the value of targeted bacterial therapeutic intervention.
Members of the resistin family were previously shown to promote insulin resistance and were linked to obesity, however, 
Muc2
À / À supernatants exhibited significant antimicrobial activity against these isolates, whereas little antimicrobial activity was seen with supernatants obtained from Muc2 À / À /Retnlb À / À mice. N ¼ 2-3 mice were used for each group and experiments were repeated three times. ANOVA *Po0.05, **Po0.001 and ***Po0.0001. ANOVA, analysis of variance; Muc, mucin.
recent studies have highlighted their role as inflammatory mediators in the intestine. 22, 27, 28 High levels of serum resistin were reported in IBD patients suggesting it as a possible marker for intestinal inflammation. 29, 30 Although RELM-b expression was found highly induced in colonic goblet cells during several models of colitis, its role has remained unclear. We, and others, have reported the transcription of lectin genes increasing concurrently with the expression of RELM-b during infectious or chemically induced colitis; 22, 31 however, its potential to regulate the makeup of the gut microbiome was untested. We now show that RELM-b promotes colitis by inducing changes in commensal bacteria through the induction of the antimicrobial lectin RegIIIb. Of note, the modest induction of RegIIIb seen in Muc2 À / À /Retnlb À / À mice indicates that there are RELM-b-independent pathways regulating its expression, potentially reflecting the upregulated transcription of IL-22 observed in the Muc2 À / À /Retnlb À / À mice. IL-22 was previously demonstrated to modulate antimicrobial molecule expression during intestinal inflammation, [32] [33] [34] including RegIIIb and RegIIIg induction.
Antimicrobial lectins such as RegIIIa, b, and g have been previously shown to protect gut homeostasis, potentially by spatially segregating the microbiota from the intestinal epithelium.
35-37 Notably, we found RegIIIb was upregulated in Muc2 À / À mice just after weaning, concurrent with a relative reduction in Lactobacilli, at least 1 month prior to overt colitis development. Thus, it takes time for the loss of Lactobacilli to promote the exaggerated pathology suffered by Muc2 À / À mice; however, the ability of oral administered Lactobacilli to ameliorate their colitis confirms their loss has a key role in the colitis development of Muc2 À / À mice. It was intriguing that RELM-b expression appeared to primarily affect Lactobacilli. This may reflect the susceptibility of these microbes to RegIIIb and other lectins, and/or their localization within the colonpotentially near the colonic epithelium. Notably, strains of Lactobacilli from humans have been well studied for their potential beneficial effects within the gastrointestinal tract. Treatment with Lactobacillus rhamnosus GG has been shown to be safe and potentially beneficial in maintaining remission in some UC patients. 38 Similar treatment in combination with Lactobacillus acidophilus was used in a clinical study to treat UC (Ref: NCT00374725), while L. reuterii administration was found to protect against spontaneous enterocolitis in IL-10 À / À mice. 39 Curiously, the effectiveness of Lactobacilli in large clinical trials has been mixed, potentially indicating only a subset of patients show benefit. This may suggest that probiotics only prove effective when they take up prolonged residence within the host intestine. Exactly how probiotic Lactobacilli confer protection to the host is still under study, but the ability of Figure 9 Increased short-chain fatty acid levels in Lactobacillus treated mice. (a) Colon contents analyzed for SCFA levels using gas chromatography demonstrated increased levels of acetic and propionic acid in Lactobacilli treated Muc2 À / À mice in comparison with untreated Muc2 À / À mice. Results shown represent an average of n ¼ 6 mice. Student's t-test *Po0.05. Muc, mucin; SCFA, short-chain fatty acid. À / À mice treated with the human probiotic mixture VSL#3 in their drinking water for one month (started at age 3 months). Right panel: Histological scoring of H&E stained colonic tissues showed no significant differences in histopathology between treated and untreated Muc2 À / À mice (b) similarly, no differences were observed in appearance of rectal prolapse and (c) stool consistency between the treated and untreated groups. However, (d) Muc2
À / À mice treated with a combination of mouse commensal Lactobacilli isolate 1 and 2, showed overt protection from colitis as revealed by H&E staining. In addition, no (e) rectal prolapses as well as (f) normally formed stools were observed in Lactobacilli treated mice. (g) Successful colonization was confirmed as colon contents of treated and untreated mice revealed increased colonization with commensal Lactobacilli isolate 1 and 2 in the Lactobacilli treated mice but not with human VSL3 treated mice. (h) RT-PCR analysis on cDNA obtained from Lactobacilli treated mice demonstrated a significant increase in the transcription of IL-22 in comparison to untreated mice n ¼ 5 per group repeated twice for (a-g), n ¼ 4 for (h). Original magnification Â 200. Student's t-test and One-way ANOVA was used for b, c, e, f, and g, respectively ***Po0.0001, **Po0.001, *Po0.05, A, crypt abscess; ANOVA, analysis of variance; cDNA, complementary DNA; H&E, hematoxylin and eosin; I, inflammatory cell infiltration; IL-22, interleukin-22; Lu, intestinal lumen; M, mucosa; Muc, mucin; O, edema; RT-PCR, reverse transcriptase-PCR; SM, sub-mucosa.
human-derived Lactobacilli to increase butyrate production by Clostridia species is one potential mechanism. 40 In contrast, Lactobacilli strains derived from mice are less studied, and we found that their supplementation to Muc2 À / À mice significantly increased acetate and propionate levels, but not butyrate. This increase in SCFA may be a key factor promoting mucosal healing in the Lactobacilli-treated Muc2 À / À mice. Notably, acetate and propionate have gained considerable attention due to their role in glucose metabolism and their ability to suppress NF-kB, making them potentially useful in the treatment of IBD. 41, 42 Moreover, our results showing an increase in the gene transcript levels of IL-22 in Lactobacilli-treated group suggests a possible wound healing role of this cytokine during intestinal inflammation. 43, 44 Thus, the transcription of IL-22 along with the milieu of elevated protective SCFA, would have significantly contributed to limit colonic tissue damage and colitis observed in Lactobacilli-treated Muc2 À / À mice. However, we do not exclude other possible reported mechanisms for the benefits of Lactobacilli treatment, such as competitive exclusion of pathogenic microbes, strengthening of tight junction proteins, and/or regulation of cytokine expression. 45, 46 In conclusion, these findings highlight a new role for intestinal goblet cells. Not only are they key protective cells that maintain the intestinal mucus barrier, but they can also act as potent drivers of intestinal inflammation, in this study, through the ability of RELM-b to promote commensal microbial dysbiosis. Although Muc2 deficiency on its own altered the gut microbiome, it was the additional actions of RELM-b that exaggerated the dysbiosis and worsened colitis in these mice. RELM-b did this by directly upregulating RegIIIb expression that exerted its antimicrobial effects on Lactobacilli. Overall, these results not only provide insight into how altered goblet cell function can contribute to intestinal inflammation, but also demonstrate that specifically identifying depleted commensal bacterial species in UC patients and selectively reconstituting the same species could prove potentially therapeutic.
METHODS
Mice. Mucin 2 (Muc2) and Resistin like molecule beta (Retnlb) deficient mice (C57BL/6 background) were crossbred to generate Muc2 À / À /Retnlb À / À mice. Genotyping was performed using a DNA extraction kit (Qiagen, Toronto, Ontario, Canada) followed by amplification of wild-type and mutated Muc2 and Retnlb alleles using PCR and agarose gels. Primer sequences were obtained from previous publications. 12, 47 All mice (including wild-type C57BL/6) were raised in-house, in sterilized, filter-topped cages, handled in biosafety cabinets, and fed autoclaved food and water under specific pathogenfree conditions. The protocols used were approved by the University of British Columbia's Animal Care Committee and in direct accordance with guidelines drafted by the Canadian Council on the Use of Laboratory Animals.
Tissue collection. Mice were anesthetized with isofluorane and killed via cervical dislocation. For microbiota analysis, fresh colon contents were collected and transferred into cryogenic vials. For histology, 0.5-cm sections of distal colon were immediately placed in 10% neutral-buffered formalin (Thermo Fisher, Waltham, MA) and left at 4 1C overnight followed by transfer into 70% ethanol and paraffin embedding to cut 5-mm sections. Distal colon sections (0.5-1 cm) were also collected and stored at À 80 1C in cryogenic vials or RNAlater (Qiagen) to run western blots and RNA extraction, respectively.
Cell culture. CMT-93 cells obtained from ATCC were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 20 mM HEPES, 1% glutamine, penicillin (100 U ml À 1 ) and streptomycin (100 mg ml À 1 ; Sigma Chemicals Co., St. Louis, MD). Cells were maintained at 37 1C in a humidified incubator with 5% CO 2. Cells grown to confluence were treated with recombinant RELM-b protein (100 ng ml À 1 ) for 4 h or left untreated as controls.
Immunostaining. Tissue sections were deparaffinized by heating at 56 1C for 10 min, cleared with xylene, and rehydrated through an ethanol gradient to water. A phosphate-buffered saline containing 2% goat or donkey serum, 1% bovine serum albumin, 0.1% Triton X-100, 0.05% Tween20, and 0.05% sodium azide was used to block the sections. Quantitative PCR analysis of cells, tissues, and stool samples.
Total RNA from CMT-93 cells and colon tissues was extracted using the Qiagen RNeasy kit, as per manufacturer's recommendations and 2 mg of RNA was used to generate complementary DNA using the Qiagen Omniscript RT kit. Colon contents were pre-weighed and DNA was extracted using the Stool DNA Mini Kit (Qiagen) according to their protocol. DNA was quantified using a NanoDrop Spectrophotometer (ND1000) and quantitative PCR was performed by adding 5 ml of either complementary DNA or stool DNA to 15 ml PCR reaction mix containing 10 ml SYBR green dye (Bio-Rad, Mississauga, Ontario, Canada) and 5 ml comprised of RNase/DNase-free water and primers to a final concentration of 0.6 mM. All reactions were assembled in duplicate and quantitative PCR carried out using a Bio-Rad Opticon2. Melting point analysis confirmed the specificity of the PCR. Results were quantified using GeneEx Macro OM 3.0 software (Bio-Rad) following the 2DDCt method. For commensal analysis, the relative abundance was determined by calculating average Ct value normalized to each primer's experimentally determined efficiency relative to the total 16S ribsosomal RNA bacteria (EUB). The specificity of Lactobacilli primers was further confirmed by ribsosomal RNA sequencing and blasting contig sequence in RDP program (East Lansing, MI). Primer sequences and reaction schemes are given in Table 1 .
Crypt isolation and antimicrobial assays. Longitudinally opened colon tissues (0.5 cm) were incubated for 2 h at 4 1C in Cell Recovery solution (Corning, NY) and gently agitated to dislodge crypts. Approximately 2,000 isolated crypts were resuspended in 40 ml of iPIPES buffer (10 mM PIPES, 137 mM NaCl, pH 7.4) and incubated at 37 1C for 30 min followed by centrifugation at 1,500 r.p.m. for 10 min to collect supernatants. Overnight bacterial cultures were serially diluted and aliquoted to 1,000 bacteria per 100 ml per well into a 96-well plate. After centrifugation at 1,500 r.p.m. for 10 min, 10 ml of the appropriate crypt supernatant was added to the bacterial pellet and incubated for 2 h. Bacterial pellets incubated with only recombinant RegIIIb protein (R&D), iPIPES buffer or water, were used as controls. The bacteria were then plated and incubated overnight at 37 1C and colony forming units counted. Preparation of whole-tissue and crypt lysates. Crypts isolated as mentioned above were lysed on ice by pipetting up and down every 10 min for 30 min in RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 0.5% sodium deoxycholate, with 1% Triton X-100, 1% phosphatase inhibitor cocktail (Thermo Scientific, Burlington, Ontario, Canada) and protease inhibitor cocktail tablets (Roche, Mannheim, Germany)). Colon tissues (500 mg) were homogenized in 300 ml of RIPA buffer using a MixerMill for 5 min at 30 Hz for 2 h at 4 1C. Supernatants from tissue and crypt homogenates were collected following centrifugation at high speed (14,000 r.p.m. for 15 min at 4 1C). The proteins in the supernatants were analyzed using the Dc Protein Assay kit (Bio-Rad).
Preparation of stool lysates. One to two stool pellets were harvested and placed in 500 ml of U9 buffer (9 M Urea, 2%CHAPS, 50 mM Tris pH 9.0). Stool pellets were homogenized (as above) with a steel bead using a MixerMill and kept at room temperature for 1 h followed by mixing with 500 ml of U1 buffer (0.9 M Urea, 2% CHAPS, 50 mM Tris pH 9.0). Samples were then centrifuged at 14,000 r.p.m. for 10 min, and the supernatant was collected and quantified using a Dc Protein Assay kit.
Western blot analysis of crypts, whole-tissue lysates, and stool samples. Lysates prepared from crypts, whole tissues and stool samples were resolved by SDS-PAGE and transferred onto 0.2 mm polyvinylidene difluoride membranes (GE Healthcare, Buckinghamshire, UK). Membranes were blocked with 5% bovine serum albumin (Sigma, Oakville, Ontario, Canada) and probed using mouse anti-RELM-b, b-actin, or sheep anti-RegIIIb (all at 1:2,000 dilution). Blots were incubated with horseradish peroxidase-conjugated anti-mouse or anti-sheep secondary antibodies (1:10,000 dilutions) and exposed to the SuperSignal West Dura substrate (Thermo). Proteins bands were visualized using a ChemiDocXRS system (Bio-Rad).
FISH staining. Stool pellets were weighed, diluted in phosphatebuffered saline and fixed overnight in 37% formalin. Samples were filtered through a 0.2 mm Whatman membrane and rehydrated using ethanol. For FISH hybridization, deparaffinized colon sections and membrane filters were incubated overnight in the dark at 37 1C with probes for either Lactobacilli AlexaFluor 488-conjugated (5 0 -GTCCATTGTGGAAGATTCCC-3 0 ) or total bacteria TexasRedconjugated EUB (5 0 -GCTGCCTCCCGTAGGAGT-3 0 ), diluted to a final concentration of 2.5 ng ml À 1 in hybridization buffer (0.9 M NaCl, 0.1 M Tris pH 7.2, 30% Formamide, 0.1% SDS). After washing in dark for 15 min in a wash buffer (0.9 M NaCl, 0.1 M Tris pH 7.2, 0.1% SDS), samples were air dried and mounted on slides using 4',6'-diamidino-2-phenylindole and visualized with a Zeiss AxioImager microscope (Göttingen, Germany). Stained bacteria were quantified as number of bacteria per gram of stool.
Histology and pathology scoring. Paraffin sections were deparaffinized and hematoxylin and eosin stained. Sections were mounted on microscope slides and visualized with a Zeiss AxioImager microscope. Histological scoring was based on previously adapted scoring systems. 48, 49 
